Related Experiment Video
Updated: Jun 27, 2026
Experimental Models to Study the Neuroprotection of Acidic Postconditioning Against Cerebral Ischemia
Published on: July 31, 2017
Current status of neuroprotection for cerebral ischemia: synoptic overview
1Department of Neurology (D4-5), University of Miami Miller School of Medicine, PO Box 016960, Miami, FL 33101, USA. mginsberg@med.miami.edu
Abstract:
Abundant preclinical studies have identified multiple mechanisms of ischemic brain injury and have provided proof of principle that strategies designed to counter these mechanisms can protect the ischemic brain. This review article emphasizes the translation of these strategies from the laboratory to clinical trials. It is a disappointing fact that many agents have been brought to clinical trial despite only modest or inconsistent preclinical evidence of neuroprotective efficacy. Preclinical investigations require rigorous attention to a variety of variables that may influence outcome. The widely touted STAIR criteria represent constructive guidelines for preclinical testing but, as experience has shown, do not increase the likelihood of translational success. Of the approximately 160 clinical trials of neuroprotection for ischemic stroke conducted as of late 2007, only approximately 40 represent larger-phase completed trials, and fully one half of the latter utilized a window to treatment of >6 hours, despite strong preclinical evidence that this delay exceeds the likely therapeutic window of efficacy in acute stroke. Other shortcomings of these trials include the use of agents lacking robust, consistent preclinical efficacy; inability to achieve adequate dosing in humans; and suboptimal clinical and statistical design features. Taken together, these factors identify areas of needed improvement for future trials.
Insights
Translating neuroprotection strategies for ischemic stroke from lab to clinic has faced challenges. Many clinical trials fail due to inconsistent preclinical data and suboptimal trial design for stroke neuroprotection.
Area of Science:
- Neuroscience
- Translational Medicine
- Stroke Research
Background:
- Preclinical studies reveal mechanisms of ischemic brain injury and potential neuroprotective strategies.
- Translating these laboratory findings into successful clinical applications remains a significant hurdle.
Purpose of the Study:
- This review critically examines the translation of neuroprotection strategies from preclinical research to clinical trials for ischemic stroke.
- It identifies key factors contributing to the limited success of these translational efforts.
Main Methods:
- The review analyzes preclinical evidence supporting neuroprotective agents.
- It evaluates the design and outcomes of numerous clinical trials for ischemic stroke neuroprotection.
- Specific attention is given to trial windows, agent efficacy, dosing, and statistical design.
Main Results:
- Many agents advanced to clinical trials lacked robust or consistent preclinical neuroprotective efficacy.
- A significant number of trials used treatment windows exceeding the likely therapeutic efficacy in acute stroke.
- Inadequate human dosing and suboptimal clinical trial designs were common shortcomings.
Conclusions:
- The translation of neuroprotection strategies for ischemic stroke faces significant challenges.
- Improvements in preclinical rigor, adherence to therapeutic windows, and optimized clinical trial design are crucial for future success.
- Addressing these factors is essential for developing effective neuroprotective therapies for stroke patients.
More Related Videos
09:48Quantification of Neurovascular Protection Following Repetitive Hypoxic Preconditioning and Transient Middle Cerebral Artery Occlusion in Mice
Published on: May 4, 2015
07:46Bilateral Common Carotid Artery Occlusion as an Adequate Preconditioning Stimulus to Induce Early Ischemic Tolerance to Focal Cerebral Ischemia
Published on: May 9, 2013
Related Concept Videos
01:15Ischemic Stroke ll: Pathophysiology
01:15Ischemic Stroke l: Introduction
01:26Transient Ischemic Attack l: Introduction
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...